22q11.2 deletion syndrome laboratory findings: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{22q11.2 deletion syndrome}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}} ==Overview== ==Laboratory Findings== * Hypocalcemia (50%)(due to hypoparathyroi...")
 
No edit summary
 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{22q11.2 deletion syndrome}}
{{22q11.2 deletion syndrome}}
Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.


{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}


==Overview==
==Overview==
Patients diagnosed with or suspected of having DGS should undergo extensive evaluation, particularly if life-threatening cardiac or immunologic deficits are present.
Testing for CBC, T and B lymphocyte panels, Echocardiography, Immunoglobulin levels, Calcium levels are some of the main ones for evaluating DGS.


==Laboratory Findings==
==Laboratory Findings==
* [[Hypocalcemia]] (50%)(due to hypoparathyroidism)
Patients diagnosed with or suspected of having DGS should undergo extensive evaluation, particularly if life-threatening cardiac or immunologic deficits are present. The following tests should merit consideration:
* [[Growth hormone]] deficiency
 
Echocardiogram to evaluate conotruncal abnormalities
 
Complete blood count with differential
 
T and B Lymphocyte subset panels
 
Flow cytometry to assess T cell repertoire
 
Immunoglobulin levels
 
Vaccine titers for evaluation of response to vaccines
 
Serum ionized calcium and phosphorus levels
 
Parathyroid hormone level
 
Chest x-ray for thymic shadow evaluation
 
Renal ultrasound for possible renal and genitourinary defects
 
Serum creatinine
 
TSH
 
Testing for growth hormone deficiency


It is important to note that the broad spectrum of disease severity makes the evaluation of DGS particularly challenging. Cases involving significant cardiac, thymic, and craniofacial deficits are more easily recognizable than those lacking severe features. Implementation of advancing genomic studies and facial recognition technology in modern medicine may assist in more effective diagnosis and evaluation of DGS patients.<ref>Kruszka P, Addissie YA, McGinn DE, Porras AR, Biggs E, Share M, Crowley TB, Chung BH, Mok GT, Mak CC, Muthukumarasamy P, Thong MK, Sirisena ND, Dissanayake VH, Paththinige CS, Prabodha LB, Mishra R, Shotelersuk V, Ekure EN, Sokunbi OJ, Kalu N, Ferreira CR, Duncan JM, Patil SJ, Jones KL, Kaplan JD, Abdul-Rahman OA, Uwineza A, Mutesa L, Moresco A, Obregon MG, Richieri-Costa A, Gil-da-Silva-Lopes VL, Adeyemo AA, Summar M, Zackai EH, McDonald-McGinn DM, Linguraru MG, Muenke M. 22q11.2 deletion syndrome in diverse populations. Am. J. Med. Genet. A. 2017 Apr;173(4):879-888.</ref>
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
[[Category:Hematology]]


{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 00:29, 28 August 2020

22q11.2 deletion syndrome Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating 22q11.2 deletion syndrome from other Diseases

Causes

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

22q11.2 deletion syndrome laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 22q11.2 deletion syndrome laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 22q11.2 deletion syndrome laboratory findings

CDC on 22q11.2 deletion syndrome laboratory findings

22q11.2 deletion syndrome laboratory findings in the news

Blogs on 22q11.2 deletion syndrome laboratory findings

Directions to Hospitals Treating 22q11.2 deletion syndrome

Risk calculators and risk factors for 22q11.2 deletion syndrome laboratory findings

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Patients diagnosed with or suspected of having DGS should undergo extensive evaluation, particularly if life-threatening cardiac or immunologic deficits are present.

Testing for CBC, T and B lymphocyte panels, Echocardiography, Immunoglobulin levels, Calcium levels are some of the main ones for evaluating DGS.

Laboratory Findings

Patients diagnosed with or suspected of having DGS should undergo extensive evaluation, particularly if life-threatening cardiac or immunologic deficits are present. The following tests should merit consideration:

Echocardiogram to evaluate conotruncal abnormalities

Complete blood count with differential

T and B Lymphocyte subset panels

Flow cytometry to assess T cell repertoire

Immunoglobulin levels

Vaccine titers for evaluation of response to vaccines

Serum ionized calcium and phosphorus levels

Parathyroid hormone level

Chest x-ray for thymic shadow evaluation

Renal ultrasound for possible renal and genitourinary defects

Serum creatinine

TSH

Testing for growth hormone deficiency

It is important to note that the broad spectrum of disease severity makes the evaluation of DGS particularly challenging. Cases involving significant cardiac, thymic, and craniofacial deficits are more easily recognizable than those lacking severe features. Implementation of advancing genomic studies and facial recognition technology in modern medicine may assist in more effective diagnosis and evaluation of DGS patients.[1]

References

  1. Kruszka P, Addissie YA, McGinn DE, Porras AR, Biggs E, Share M, Crowley TB, Chung BH, Mok GT, Mak CC, Muthukumarasamy P, Thong MK, Sirisena ND, Dissanayake VH, Paththinige CS, Prabodha LB, Mishra R, Shotelersuk V, Ekure EN, Sokunbi OJ, Kalu N, Ferreira CR, Duncan JM, Patil SJ, Jones KL, Kaplan JD, Abdul-Rahman OA, Uwineza A, Mutesa L, Moresco A, Obregon MG, Richieri-Costa A, Gil-da-Silva-Lopes VL, Adeyemo AA, Summar M, Zackai EH, McDonald-McGinn DM, Linguraru MG, Muenke M. 22q11.2 deletion syndrome in diverse populations. Am. J. Med. Genet. A. 2017 Apr;173(4):879-888.

Template:WH Template:WS